Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Arase, Yasuji; Suzuki, Fumitaka; Kobayashi, Mariko; Suzuki, Yoshiyuki; Kawamura, Yusuke; Matsumoto, Naoki; Akuta, Norio; Imai, Norihisa; Kobayashi, Masahiro; Sezaki, Hitomi; Saito, Satoshi; Hosaka, Tetsuya; Ikeda, Kenji; Kumada, Hiromitsu; Ohmoto, Yuki; Amakawa, Kazuhisa; Tsuji, Hiroshi; Hsieh, Shiun Dong; Kobayashi, Tetsurou

doi:10.1111/j.1872-034x.2011.00798.x

Cited by 25 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our previous study has showed that sitagliptin therapy is effective and safe for chronic hepatitis C patients with T2DM . The present study suggests that sitagliptin therapy is effective and safe for NAFLD patients with T2DM.…”

Section: Discussionsupporting

confidence: 64%

“…Our previous study has showed that sitagliptin therapy is effective and safe for chronic hepatitis C patients with T2DM. 27 The present study suggests that sitagliptin therapy is effective and safe for NAFLD patients with T2DM. Regarding efficacy, the improvement of HbA1c level at 48 weeks after the initiation of sitagliptin was 0.9% in patients with hepatitis C virus and 0.7% in those with NAFLD.…”

Section: W E Have Described the Efficacy And Side-effectssupporting

confidence: 49%

See 1 more Smart Citation

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Arase

Kawamura

Seko

et al. 2013

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 64%

Section: W E Have Described the Efficacy And Side-effectssupporting

confidence: 49%

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Arase

Kawamura

Seko

et al. 2013

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efficacy of sitagliptin therapy has been shown in patients with T2DM complicated by NAFLD [27][28][29][30] , NASH [31] or CLD caused by hepatitis C virus [32] . However, one report suggested that NAFLD may adversely affect the glycaemic control obtained with sitagliptin [33] .…”

Section: Hepatic Safetymentioning

confidence: 99%

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Scheen

2014

Clin Pharmacokinet

View full text Add to dashboard Cite

SUMMARYPatients with type 2 diabetes have an increased risk of chronic liver disease such as nonalcoholic fatty liver disease and steatohepatitis, and about one third of cirrhotic patients have diabetes. However, the use of several antidiabetic agents, such as metformin and sulphonylureas, may be a concern in case of hepatic impairment (HI). New glucose-lowering agents targeting the incretin system are increasingly used for the management of type 2 diabetes. Incretin-based therapies comprise oral inhibitors of dipeptidyl peptidase-4 (DPP-4) (gliptins) or injectable glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review summarizes the available data regarding the use of both incretin-based therapies in patients with HI. In contrast to old glucose-lowering agents, they were evaluated in specifically designed acute pharmacokinetic studies in patients with various degrees of HI and -Obese patients with type 2 diabetes often have non-alcoholic fatty liver disease or steatohepatitis and the use of incretin-based therapies appears mostly favourable in these patients regarding both efficacy and safety.-There is no reported clinical experience with the use of either DPP-4 inhibitors or GLP-1 receptor agonists in diabetic patients with moderate to severe hepatic impairment, so that caution is required in patients with advanced cirrhosis.

show abstract

“…The study concluded that sitagliptin is effective and safe for the treatment of T2DM complicated with HCV positive CLD. [80] In an observational pilot study, paired liver biopsies from 15 patients with diabetes and NASH before and after 1 year of therapy with sitagliptin 100 mg once daily were studied. Sitagliptin resulted in a significant decrease in ballooning and NASH scores, while the reduction in the steatosis score was of borderline statistical significance.…”

Section: Methodsmentioning

confidence: 99%

Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment

Gangopadhyay

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Liver disease is an important cause of mortality in type 2 diabetes mellitus (T2DM). It is estimated that diabetes is the most common cause of liver disease in the United States. Virtually, entire spectrum of liver disease is seen in T2DM including abnormal liver enzymes, nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, and acute liver failure. The treatment of diabetes mellitus (DM) in cirrhotic patients has particular challenges as follows: (1) about half the patients have malnutrition; (2) patients already have advanced liver disease when clinical DM is diagnosed; (3) most of the oral antidiabetic agents (ADAs) are metabolized in the liver; (4) patients often have episodes of hypoglycemia. The aim of this consensus group convened during the National Insulin Summit 2015, Puducherry, was to focus on the challenges with glycemic management, with particular emphasis to safety of ADAs across stages of liver dysfunction. Published literature, product labels, and major clinical guidelines were reviewed and summarized. The drug classes included are biguanides (metformin), the second- or third-generation sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and currently available insulins. Consensus recommendations have been drafted for glycemic targets and dose modifications of all ADAs. These can aid clinicians in managing patients with diabetes and liver disease.

show abstract

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Abstract: Our results indicate that sitagliptin is effective and safe for the treatment of T2DM complicated with HCV positive chronic liver disease.

Cited by 25 publications

References 26 publications

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment

Contact Info

Product

Resources

About